Loading

Cenyx Biotech, Inc.

June 16, 2025
Company Presentation
Inflammation
Cenyx Biotech Inc. is a pioneering nanomedicine company developing first-in-human cerium oxide-based nanozyme for acute and chronic inflammatory diseases with high unmet needs. Our lead candidate, CX213, has received FDA IND approval and orphan drug designation for SAH-induced inflammation, a life-threatening condition with no approved therapy. Phase 1 trials will begin in 2Q 2025 in the US, with an expedited market entry strategy targeting commercialization by 2028. Our second pipeline, CX301, is advancing toward IND approval by 2Q 2025 for multiple types of acute kidney injury. CENYX leverages its proprietary INNOSURFACE® platform to develop next-gen anti-inflammatory nanozymes across multiple delivery routes. Supported by national grants and in-house GMP manufacturing, we aim to transform inflammatory disease treatment. CENYX seeks strategic partners to accelerate clinical progress and global commercialization.
Cenyx Biotech, Inc.
Company HQ City: Seoul
Company HQ State: Seoul
Company HQ Country: Korea, Republic of
Year Founded: 2016
Lead Product in Development: CX213 (cerium oxide-based nanozyme)

CEO

Seung-Hoon Lee, MD, PhD, FAHA

Year Founded

2016

Development Phase of Lead Product

Phase I

Number of Unlicensed Products Looking for Licensing

4

When you expect your next catalyst update?

CX213 first-in-human (Phase 1a) clinical trial

What is your next catalyst (value inflection) update?

CX213 Phase 1a initiation by April 2025, final data available by September 2025

Website

https://www.cenyxbiotech.com/en/
Primary Speaker
Jinyoung Chung
Jinyoung Chung, PharmD
Sr. Manager
Cenyx Biotech, Inc.

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

BIO HELIX SPONSORS